RxDoctor Payments Data

Stan Whitney, MD

Neurology · Tallahassee, FLNPI 1942306824

Payments from drug & device makers

$16,331in general payments, 2019–2025

Across 862 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$1K
  • Lilly USA, LLC$1K
  • UCB, Inc.$1K
  • Eisai Inc.$875
  • AstraZeneca$774
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$350%
  • Food & beverage$16,283100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)106$1,315
Novartis60$1,143
Lilly USA, LLC59$1,123
UCB, Inc.39$1,005
Eisai Inc.42$875
AstraZeneca34$774
Amgen(2 entities)37$759
Biogen37$711
Pfizer35$661
Teva Pharmaceuticals USA, Inc.35$657
EMD Serono, Inc.29$568
Sanofi26$525
Lundbeck LLC20$439
Genentech USA, Inc.18$368
Greenwich Biosciences, Inc.18$363
Acadia Pharmaceuticals Inc18$361
Jazz Pharmaceuticals Inc.16$345
SK Life Science, Inc.17$344
Tanabe Pharma America, Inc.18$316
Adamas Pharmaceuticals, Inc.18$310
Supernus Pharmaceuticals, Inc.30$309
Neurocrine Biosciences, Inc.10$200
Otsuka America Pharmaceutical, Inc.9$182
Neurelis, Inc.8$163
Octapharma USA, Inc.7$162
Kyowa Kirin, Inc.9$156
TG Therapeutics, Inc.5$155
Biohaven Pharmaceuticals, Inc.10$148
Biohaven Pharmaceutical Holding Company Ltd.9$137
Sunovion Pharmaceuticals Inc.6$126
Argenx US, Inc.4$115
Abbott3$108
Boston Scientific5$108
CSL Behring5$96
Grifols USA, LLC4$92
GE HealthCare4$76
Takeda Pharmaceuticals U.S.A., Inc.3$76
Catalyst Pharmaceuticals, Inc.3$75
Livanova USA, Inc.3$73
Sumitomo Pharma America, Inc.3$72
Impel Pharmaceuticals Inc.4$64
Mallinckrodt Hospital Products Inc.2$62
Scilex Pharmaceuticals Inc.3$52
Upsher-smith Laboratories LLC3$52
Acorda Therapeutics, Inc3$50
Axsome Therapeutics, Inc.2$49
Johnson & Johnson3$48
Bristol Myers Squibb2$44
Merck3$39
Medtronic2$38
Merz Pharmaceuticals, LLC1$36
Amneal Pharmaceuticals LLC2$34
Assertio Therapeutics, Inc.2$34
Avion Pharmaceuticals1$33
MDD US Operations, LLC2$30
Azurity Pharmaceuticals, Inc.1$22
Mallinckrodt Enterprises LLC1$18
Zyla Life Sciences, Inc.1$12
Portola Pharmaceuticals, LLC1$11
Avanir Pharmaceuticals, Inc.1$11

How this compares

$16,331 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$208,394
Medicare patients
451
Services billed
2,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$69,514
Emgality PenGalcanezumab-Gnlm67$46,369
Nurtec OdtRimegepant Sulfate20$33,490
TopamaxTopiramate13$18,995
BriviactBrivaracetam14$18,184
UbrelvyUbrogepant11$17,114
Lacosamide103$8,014
Carbamazepine ErCarbamazepine13$6,768
Gabapentin368$5,504
Carbidopa-LevodopaCarbidopa/Levodopa99$3,939
Levetiracetam85$3,842
Pregabalin93$3,521
Donepezil Hcl224$2,206
Sumatriptan Succinate56$1,709
Oxcarbazepine18$1,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$76$69,51414 claims
PfizerNurtec Odt$661$33,49020 claims
UCB, Inc.Briviact$1,005$18,18414 claims
AbbVieUbrelvy$1,315$17,11411 claims
Upsher-smith Laboratories LLCTopiramate$52$1,404101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →